Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects

AMD3100/Plerixafor overcomes immune inhibition by the CXCL12–KRT19 coating on pancreatic and colorectal cancer cells

(2021) Douglas T. Fearon et al.   BRITISH JOURNAL OF CANCER

B cells and tertiary lymphoid structures promote immunotherapy response

(2020) Beth A. Helmink et al.   NATURE

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

(2020) Bruno Bockorny et al.   NATURE MEDICINE

The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer

(2020) Jérémy Bastid et al.   Frontiers in Immunology

Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer

(2019) Ivy X. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunotherapy in colorectal cancer: rationale, challenges and potential

(2019) Karuna Ganesh et al.   Nature Reviews Gastroenterology & Hepatology

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia

(2019) Michael Steurer et al.   HAEMATOLOGICA

Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma

(2019) Reena P Thomas et al.   CLINICAL CANCER RESEARCH

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

(2019) Irene M. Ghobrial et al.   CLINICAL CANCER RESEARCH

Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials

(2018) Sirisha L. Mushti et al.   CLINICAL CANCER RESEARCH

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations

(2018) Zishuo I. Hu et al.   CLINICAL CANCER RESEARCH

Design and conduct of early clinical studies of immunotherapy agent combinations: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies

(2018) M Smoragiewicz et al.   ANNALS OF ONCOLOGY

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

(2018) A Marabelle et al.   ANNALS OF ONCOLOGY

Differences in Treatment Effect Size Between Overall Survival and Progression-Free Survival in Immunotherapy Trials: A Meta-Epidemiologic Study of Trials With Results Posted at ClinicalTrials.gov

(2017) Aidan Tan et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

(2017) H Ludwig et al.   LEUKEMIA

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

(2017) Jennifer L. Guerriero et al.   NATURE

Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade

(2017) Dirk Zboralski et al.   Cancer Immunology Research

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

(2017) et al.   JAMA Oncology

Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients

(2016) Niels Halama et al.   CANCER CELL

Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?

(2016) E. Pure et al.   Cancer Immunology Research

Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma

(2016) Isabel Poschke et al.   OncoImmunology

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer® therapeutics

(2015) Axel Vater et al.   DRUG DISCOVERY TODAY

Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983

(2015) Erik Tanis et al.   EUROPEAN JOURNAL OF CANCER

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting IL-17B–IL-17RB signaling with an anti–IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines

(2015) Heng-Hsiung Wu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

(2015) Ignacio Garrido-Laguna et al.   Nature Reviews Clinical Oncology

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomised trials

(2014) Clemens Giessen et al.   ACTA ONCOLOGICA

SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy

(2014) Aldo M. Roccaro et al.   Cell Reports

The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization

(2013) J. Hoellenriegel et al.   BLOOD

Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First-in-Class Mirror-Image Oligonucleotide Inhibitor of CXCL12

(2013) A Vater et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats

(2013) Shie-Chau Liu et al.   NEURO-ONCOLOGY

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

(2013) C. Feig et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?

(2013) L. M. Coussens et al.   SCIENCE

Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration

(2013) Niels Halama et al.   OncoImmunology

Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials

(2012) C. Giessen et al.   CLINICAL CANCER RESEARCH

Sequential metastases of colorectal cancer

(2012) Sophia Keim et al.   OncoImmunology

IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma

(2011) Jiankun Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy

(2011) N. Halama et al.   CANCER RESEARCH

The prognostic impact of anti-cancer immune response: a novel classification of cancer patients

(2011) Gabriela Bindea et al.   Seminars in Immunopathology

Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF

(2009) Luigi Dolcetti et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer

(2009) Christine A. Iacobuzio-Donahue et al.   JOURNAL OF CLINICAL ONCOLOGY

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION